Paratek Pharmaceuticals, Inc. (PRTK) Reached Yearly Low on April, 22 at $11.00

Lloyd Doyle
April 23, 2018

Also, VP Adam Woodrow sold 14,333 shares of the firm's stock in a transaction on Tuesday, February 6th. About 1.65 million shares traded. Bancolombia S.A. (NYSE:CIB) has risen 6.47% since April 23, 2017 and is uptrending.

The stock of Paratek Pharmaceuticals, Inc. Following the completion of the transaction, the chairman now directly owns 199,730 shares of the company's stock, valued at approximately $2,536,571. Following the transaction, the vice president now directly owns 62,367 shares of the company's stock, valued at $865,030.29. Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) has $345.87 million MC. Russell Investments Group Ltd. now owns 118,533 shares of the specialty pharmaceutical company's stock worth $2,975,000 after buying an additional 54,746 shares in the last quarter. The company's stock had a trading volume of 2,455,811 shares, compared to its average volume of 564,661. Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) has declined 26.88% since April 22, 2017 and is downtrending. The stock underperformed the S&P 500 by 38.43%. The business had revenue of $5.07 million during the quarter, compared to the consensus estimate of $5.00 million. analysts anticipate that Paratek Pharmaceuticals will post -3.43 earnings per share for the current year. Therefore 90% are positive. (NASDAQ:PRTK) has "Buy" rating given by H.C. Wainwright. The firm has "Overweight" rating given on Thursday, July 23 by JP Morgan. Finally, Raymond James reissued an "outperform" rating and set a $36.00 price objective on shares of Paratek Pharmaceuticals in a report on Friday, March 2nd. As per Thursday, October 27, the company rating was reinitiated by Leerink Swann. In Wednesday, November 8 report Cantor Fitzgerald maintained the stock with "Buy" rating. Zacks downgraded Paratek Pharmaceuticals, Inc. Paratek Pharma Inc (NASDAQ:PRTK)'s price sits -18.6% off from its SMA 50 of $13.48 and -42.84% away from the SMA 200 which is at $17.28.

In other news, CFO Douglas W. Pagan sold 5,237 shares of the company's stock in a transaction dated Monday, April 9th.

Wavetrue Inc (NASDAQ:PRTK) institutional sentiment decreased to 0.91 in 2017 Q4. That's change of 0.63, from 2017Q3's 1.54. The ratio is negative, as 49 institutional investors started new or increased holdings, while 54 decreased and sold their holdings in Wavetrue Inc. 12 funds acquired holdings and 37 increased holdings. Blackrock owns 1.90 million shares. Barclays Public Ltd holds 0% in Paratek Pharmaceuticals, Inc. Paratek Pharma Inc (NASDAQ:PRTK)'s price to sales ratio for trailing twelve month stands at 33.06, whereas its price to book ratio for the most recent quarters is at 3.73. (NASDAQ:PRTK). Opus Point Prtn Mgmt Ltd Liability Co holds 40,000 shares or 0.62% of its portfolio. Parallax Volatility Advisers Lp stated it has 12,332 shares. Brown Brothers Harriman & holds 287,902 shs. (NASDAQ:PRTK). Deutsche National Bank & Trust Ag has 0% invested in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK). Wells Fargo & Company Mn reported 19,358 shs stake. Abingworth Llp stated it has 13.5% in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) for 376,285 shares.

WARNING: "Paratek Pharmaceuticals, Inc". State Of Wisconsin Board reported 16,000 shares or 0% of all its holdings. Parametric Portfolio Lc has 0% invested in Paratek Pharmaceuticals, Inc.

Total analysts of 5 have positions in Paratek Pharmaceuticals (NASDAQ:PRTK) as follows: 5 rated it a "Buy", 0 with "Sell" and 0 with "Hold". Following the sale, the chief financial officer now owns 77,083 shares in the company, valued at approximately $978,954.10. (NASDAQ:PRTK) for 1,457 shs. Pacad Inv Limited owns 3,800 shs or 0.02% of their United States capital. It also reduced its holding in Time Warner Inc (NYSE:TWX) by 398,113 shares in the quarter, leaving it with 948,759 shares, and cut its stake in Altaba Inc. In the last ninety days, insiders sold 68,385 shares of company stock worth $925,282. The insider LYNCH THOMAS J sold 76,183 shares worth $7.73M. Therefore 17% are positive. Finally, ValuEngine downgraded Paratek Pharmaceuticals from a "sell" rating to a "strong sell" rating in a report on Friday, February 2nd. The company posted an earnings surprise of -4%. Stifel Nicolaus maintained TE Connectivity Ltd. (NYSE:TEL) rating on Wednesday, January 24. The stock presently has an average rating of "Buy" and a consensus price target of $40.00. RBC Capital Markets maintained it with "Outperform" rating and $63 target in Friday, July 1 report. The company was maintained on Thursday, October 29 by RBC Capital Markets. The company was initiated on Thursday, July 23 by Gabelli. The company was maintained on Friday, January 15 by RBC Capital Markets. The stock has "Hold" rating by Zacks on Wednesday, September 2.

Other reports by Iphone Fresh

Discuss This Article